Fennec Pharmaceuticals Inc. Registered Shares o.N.
- BID
8.85
- ASK
8.95
- 226 Units223 Units
- 07/21, 19:30:09 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
19.31%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.30 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 8.85 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 07:16:19 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 8.85 | 8.25 |
| PREV. DAY'S PRICE | 8.65 | (07/20) |
| CHANGE DAY BEFORE | +0.20 | 2.31 % |
| 52 WEEK HIGH / LOW | 9.75 (07/14) | 4.74 (04/13) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.56 | -0.01 | -0.30 | 0.21 | 0.78 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | 43.75 | 11.73 |
PRICE - BOOK RATIO | - | - | 7.42 | - | - |
PRICE - SALES RATIO | 14.03 | 3.63 | 4.93 | - | - |
PRICE - CASH FLOW RATIO | - | 6.39 | - | - | - |
Master Data
| WKN | A12A5F |
| ISIN | CA31447P1009 |
| SYMBOL | RV41 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Fennec Pharma |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -7.98 % | 15.33 % | 53.10 % | 38.40 % | 19.31 % | 13.07 % | 57.27 % | 35.16 % |
| HIGH | 9.75 | 9.75 | 9.75 | 9.75 | 9.75 | 10.40 | 10.40 | 9.75 |
| LOW | 8.40 | 7.25 | 5.10 | 4.74 | 4.74 | 3.70 | 3.40 | 4.74 |
Dividende
pro Aktie
Fennec Pharma does not deliver dividend information
Company profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.